Den Europæiske Union - engelsk - EMA (European Medicines Agency)

ucb pharma sa  - certolizumab pegol - arthritis, rheumatoid - immunosuppressants - rheumatoid arthritiscimzia, in combination with methotrexate (mtx), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmards) including mtx, has been inadequate. cimzia can be given as monotherapy in case of intolerance to mtx or when continued treatment with mtx is inappropriatethe treatment of severe, active and progressive ra in adults not previously treated with mtx or other dmards.cimzia has been shown to reduce the rate of progression of joint damage as measured by x ray and to improve physical function, when given in combination with mtx.axial spondyloarthritis cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:ankylosing spondylitis (as)adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids).axial spondyloarthritis without radiogra

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia a (congenital factor viii deficiency).

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohn disease - immunosuppressants - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate.cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

novo nordisk a/s - nonacog beta pegol - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency)., refixia can be used for all age groups.,

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

baxalta innovations gmbh - rurioctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia a (congenital factor viii deficiency).

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia a (congenital factor viii deficiency).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Israel - engelsk - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa pegol - powder and solvent for solution for injection - turoctocog alfa pegol 1000 iu/vial - treatment and prophylaxis of bleeding in previously treated patients with haemophilia a (congenital factor viii disorder).esperoct® does not contain pharmacologically active quantities of von willebrand factor and is, therefore, unsuitable for the treatment of von willebrand disease.